Information de reference pour ce titreAccession Number: | 00005597-201211000-00020.
|
Author: | Boumber, Y 1; Kantarjian, H 2; Jorgensen, J 3; Wen, S 4; Faderl, S 2; Castoro, R 2; Autry, J 2; Garcia-Manero, G 2; Borthakur, G 2; Jabbour, E 2; Estrov, Z 2; Cortes, J 2; Issa, J-P 2; Ravandi, F 2
|
Institution: | (1)Hematology/Oncology Fellowship Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; (2)Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; (3)Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (4)Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA E-mail: [email protected]
|
Title: | A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.[Letter]
|
Source: | Leukemia. 26(11):2428-2431, November 2012.
|
References: | 1 Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
2 Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
3 Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
4 Cashen AF, Schiller GJ, O'Donnell MR, Multicenter DiPersio JF. phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 556-561.
5 Kroeger H, Jelinek J, Estecio MR, He R, Kondo K, Chung W et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 2008; 112: 1366-1373.
6 Agrawal S, Unterberg M, Koschmieder S, zur Stadt U, Brunnberg U, Verbeek W et al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res 2007; 67: 1370-1377.
7 Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010; 28: 605-613.
8 Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K et al. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res 2007; 67: 1997-2005.
9 Wong KY, So CC, Loong F, Chung LP, Lam WW, Liang R et al. Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One 2011; 6: e19027.
10 San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98: 1746-1751.
11 Stone RM. Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML? Best Pract Res Clin Haematol 2011; 24: 509-514.
12 Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012; 119: 332-341.
13 Estecio MR, Gharibyan V, Shen L, Ibrahim AE, Doshi K, He R et al. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One 2007; 2: e399.
14 Bullinger L, Ehrich M, Dohner K, Schlenk RF, Dohner H, Nelson MR et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 2010; 115: 636-642.
|
Language: | English.
|
Document Type: | Letters To the Editor.
|
Journal Subset: | Clinical Medicine. Life & Biomedical Sciences.
|
ISSN: | 0887-6924
|
NLM Journal Code: | leu, 8704895
|
DOI Number: | https://dx.doi.org/10.1038/leu.2...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|